We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The latest official price and production statistics from Hungary
and Poland indicate that government measures to control rising drug prices are
continuing to bite.
Torrent Pharmaceuticals audited results for the quarter and year ended March
31, 2005, is as follows: The company has posted 66.32 percent decline in net
profit at Rs 3.30 crore for the quarter ended March 31, 2005, as compared to
Rs 9.80 crore for the quarter ended March 31, 2004.
Spectrum Pharmaceuticals announced that it has acquired worldwide exclusive
rights to a lucanthone from Dr. Robert E. Bases, the inventor of a method of
treating cancer of the central nervous system through the administration of
lucanthone and radiation. Lucanthone is currently in Phase II clinical trials
at Montefiore Medical Center.
Teva Pharmaceutical Industries currently has specialized biogeneric R&D
centers in Lithuania, Mexico and China, as well as a recently established development
team in Israel.
Sucampo Pharmaceuticals (Sucampo), a leader in functional fatty acid research
and development, announced that it received $20 million from its business partner,
Takeda Pharmaceutical Company (Takeda), as payment for achieving a development
milestone -- initiation of a Phase III clinical trial of lubiprostone to
treat patients with constipation-predominant irritable bowel syndrome (IBS-C).
Corautus Genetics and Boehringer Ingelheim Austria GmbH announced that they
have entered into a long term manufacturing agreement to produce VEGF-2 (Vascular
Endothelial Growth Factor 2) plasmid DNA for a Phase III trial and future commercial
use for the treatment of cardiovascular disease (severe angina) and other indications.
BioMarin Pharmaceutical and
Serono announced that they have formed a strategic alliance for the further
development and commercialization of two BioMarin product candidates, Phenoptin
(sapropterin hydrochloride) and Phenylase (phenylalanine ammonia lyase).
Fiocruz, a government drug manufacturer linked to Brazil's health ministry,
is to boost its annual output from 1.7bn units per year to 4.5bn with the opening
of a new production facility. The 40,000 square metre unit, acquired from UK
drug major GlaxoSmithKline last year, has reportedly cost some BRL18mn (US$7.27mn).